Literature DB >> 2026489

Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics.

D S Zaharko1, J A Kelley, J E Tomaszewski, L Hegedus, N R Hartman.   

Abstract

A hybrid compartmental-physiological model for cyclopentenyl cytosine (CPE-C) is designed on the basis of early limited rodent pharmacokinetic data. Application of model independent pharmacokinetics and biochemical knowledge was first used to conceptualize such a model. The approach was to scale the physiological parameters of the model (compartmental clearances) and keep constant the anatomic parameters of the model (compartment volumes). Scaling of physiological mechanisms was based on body weight/surface area ratios. Using these principles, simulations with the model can reasonably anticipate the in vivo behavior of (CPE-C) in several species (mouse, rat, dog). The model is useful in understanding species differences in pharmacokinetic behavior of CPE-C.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2026489     DOI: 10.1007/bf00194539

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  15 in total

1.  Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase.

Authors:  G J Kang; D A Cooney; J D Moyer; J A Kelley; H Y Kim; V E Marquez; D G Johns
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

2.  Transport and binding of methotrexate in vivo.

Authors:  R L Dedrick; D S Zaharko; R J Lutz
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

3.  Animal scale-up.

Authors:  R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

4.  Mlab--a mathematical modeling tool.

Authors:  G D Knott
Journal:  Comput Programs Biomed       Date:  1979-12

5.  Cyclopentenyluridine and cyclopentenylcytidine analogues as inhibitors of uridine-cytidine kinase.

Authors:  M I Lim; J D Moyer; R I Cysyk; V E Marquez
Journal:  J Med Chem       Date:  1984-12       Impact factor: 7.446

6.  Cyclopentenyl cytidine analogue. An inhibitor of cytidine triphosphate synthesis in human colon carcinoma cells.

Authors:  R I Glazer; M C Knode; M I Lim; V E Marquez
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

7.  Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.

Authors:  V E Marquez; M I Lim; S P Treanor; J Plowman; M A Priest; A Markovac; M S Khan; B Kaskar; J S Driscoll
Journal:  J Med Chem       Date:  1988-09       Impact factor: 7.446

8.  Species similarities in pharmacokinetics.

Authors:  R L Dedrick; K B Bischoff
Journal:  Fed Proc       Date:  1980-01

9.  Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice.

Authors:  J D Moyer; N M Malinowski; S P Treanor; V E Marquez
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

10.  Extrapolation of experimental data from animals to man.

Authors:  G N Krasovskii
Journal:  Environ Health Perspect       Date:  1976-02       Impact factor: 9.031

View more
  3 in total

1.  In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.

Authors:  D A Volpe; D L Du; C K Grieshaber; M J Murphy
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.

Authors:  V Reichelová; G Juliusson; T Spasokoukotskaja; S Eriksson; J Liliemark
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Authors:  P M Politi; F Xie; W Dahut; H Ford; J A Kelley; A Bastian; A Setser; C J Allegra; A P Chen; J M Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.